📣 VC round data is live. Check it out!

Mentice Valuation Multiples

Discover Mentice's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like SOFTMAX, OssDsign, Insung Information, Elutia and more.

Mentice Overview

About Mentice

Mentice AB is engaged in the provision of software and hardware simulation solutions for endovascular therapies. Its solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. It operates through three segments: Mentice VIST, Physical Sim, and Ankyras. Geographically majority of the revenue is generated from the Americas, then followed by EMEA.


Founded

1998

HQ

Sweden

Employees

131

Financials (LTM)

Revenue: $32M
EBITDA: $1M

EV

$41M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Mentice Financials

Mentice reported last 12-month revenue of $32M and EBITDA of $1M.

In the same LTM period, Mentice generated $29M in gross profit, $1M in EBITDA, and had net loss of ($2M).

Revenue (LTM)


Mentice P&L

In the most recent fiscal year, Mentice reported revenue of $31M and EBITDA of $472K.

Mentice is unprofitable as of last fiscal year, with gross margin of 87%, EBITDA margin of 2%, and net margin of (11%).

See analyst estimates for Mentice
LTMLast FY202320242025202620272028
Revenue$32M$31M$29M$31M$30M
Gross Profit$29M$27M$25M$28M$27M
Gross Margin90%87%86%89%90%
EBITDA$1M$472K$3M$2M$472K
EBITDA Margin4%2%11%6%2%
EBIT Margin(6%)(10%)(0%)(4%)(11%)
Net Profit($2M)($3M)($303K)($2M)($3M)
Net Margin(7%)(11%)(1%)(6%)(12%)

Financial data powered by Morningstar, Inc.

Mentice Stock Performance

Mentice has current market cap of $45M, and enterprise value of $41M.

Market Cap Evolution


Mentice's stock price is $1.62.

Mentice share price increased by 5.8% in the last 30 days, and decreased by 0.1% in the last year.

Mentice has an EPS (earnings per share) of $-0.12.

See more trading valuation data for Mentice
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$41M$45M6.7%5.8%12.5%-0.1%$-0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Mentice Valuation Multiples

Mentice trades at 1.3x EV/Revenue multiple, and 31.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Mentice

EV / Revenue (LTM)


Mentice Financial Valuation Multiples

As of June 3, 2026, Mentice has market cap of $45M and EV of $41M.

Mentice has a P/E ratio of (19.4x).

LTMLast FY202320242025202620272028
EV/Revenue1.3x1.3x1.4x1.3x1.4x
EV/EBITDA31.3x87.0x13.2x20.9x87.0x
EV/EBIT(21.5x)(13.4x)n/m(30.9x)(12.2x)
EV/Gross Profit1.4x1.5x1.6x1.5x1.5x
P/E(19.4x)(13.1x)(150.3x)(23.0x)(13.1x)
EV/FCF(104.9x)(10.7x)13.0xn/m(10.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Mentice Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Mentice Margins & Growth Rates

Mentice grew revenue by 8% and EBITDA by 436% in the last fiscal year.

In the most recent fiscal year, Mentice reported gross margin of 87%, EBITDA margin of 2%, and net margin of (11%).

See estimated margins and future growth rates for Mentice

Mentice Margins

Last FY202420252026202720282029
Gross Margin87%89%90%89%
EBITDA Margin2%6%2%8%
EBIT Margin(10%)(4%)(11%)(1%)
Net Margin(11%)(6%)(12%)(2%)
FCF Margin(12%)1%(13%)14%

Mentice Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth8%6%(4%)11%
Gross Profit Growth10%9%(2%)10%
EBITDA Growth436%(37%)(76%)436%
EBIT Growth(89%)1726%154%(90%)
Net Profit Growth(80%)554%76%(80%)
FCF Growth(218%)(95%)(2514%)(218%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Mentice Operational KPIs

Mentice's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Mentice's Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Mentice's Rule of X is 35% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Mentice
LTMLast FY202320242025202620272028
Rule of 4013%19%---
Bessemer Rule of X27%35%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.2M---
Opex to Revenue-98%87%93%101%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Mentice Competitors

Mentice competitors include SOFTMAX, OssDsign, Insung Information, Elutia, Biohit, Data Horizon, Sensus Healthcare, Rocket Doctor AI, Baumer and InspireMD.

Most Mentice public comparables operate across Healthcare Software, Medical Devices, HealthTech, B2B SaaS, Vertical SaaS and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
SOFTMAX1.0x1.0x8.5x-
OssDsign1.3x1.4x(6.5x)(5.9x)
Insung Information0.2x-(38399.5x)-
Elutia1.8x1.8x(1.7x)(1.5x)
Biohit2.3x-10.9x-
Data Horizon3.0x-(4.9x)-
Sensus Healthcare1.1x1.1x(3.0x)(2.9x)
Rocket Doctor AI34.2x19.9x(8.3x)(9.9x)

This data is available for Pro users. Sign up to see all Mentice competitors and their valuation data.

Start Free Trial

Acquisitions by Mentice

Mentice has acquired 4 companies to date.

Last acquisition by Mentice was on June 9th 2022. Mentice acquired Ankyras for $3M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Mentice

Ankyras
MyIRlog
Vascular Simulations
MSC - Medical Products
Description
Ankyras is a medical technology company offering patient-specific simulation software for braided stents in intracranial aneurysm treatments. The platform simulates deployment dynamics, predicts occlusion rates, and optimizes implantation parameters using finite element analysis on patient CT angiography data. Developed for neurointerventionalists, it integrates with major imaging systems and supports Flow Re-Direction Endoluminal Device stents from MicroVention-Terumo. Based in Italy, Ankyras launched commercially in Europe in 2022 following CE Mark approval and partners with hospitals in Milan and Barcelona for validation studies.
-
Vascular Simulations is a Boston-based medical technology company that creates patient-specific 3D printed vascular models for realistic simulation of endovascular procedures using actual medical devices in physical anatomies replicating human vessels.
MSC - Medical Products is a designer and supplier of medical simulation devices targeting physician training and sales demonstrations. The company produces anatomical models, procedural trainers, and virtual reality simulators for cardiology, orthopedics, and surgical specialties. Distributed to hospitals and medical device firms, its products facilitate hands-on education to accelerate adoption of new therapies.
HQ CountrySpainUnited StatesUnited StatesUnited States
HQ City
Barcelona
-
New York City, NY
Denver, CO
Deal Date9 Jun 20228 Oct 20201 Oct 202020 Dec 2017
Valuation$3M$200K$6Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Mentice acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Mentice

When was Mentice founded?Mentice was founded in 1998.
Where is Mentice headquartered?Mentice is headquartered in Sweden.
How many employees does Mentice have?As of today, Mentice has over 131 employees.
Is Mentice publicly listed?Yes, Mentice is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Mentice?Mentice trades under MNTC ticker.
When did Mentice go public?Mentice went public in 2019.
Who are competitors of Mentice?Mentice main competitors include SOFTMAX, OssDsign, Insung Information, Elutia, Biohit, Data Horizon, Sensus Healthcare, Rocket Doctor AI, Baumer, InspireMD.
What is the current market cap of Mentice?Mentice's current market cap is $45M.
What is the current revenue of Mentice?Mentice's last 12 months revenue is $32M.
What is the current revenue growth of Mentice?Mentice revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of Mentice?Current revenue multiple of Mentice is 1.3x.
What is the current EBITDA of Mentice?Mentice's last 12 months EBITDA is $1M.
What is Mentice's EBITDA margin?Mentice's last 12 months EBITDA margin is 4%.
What is the current EV/EBITDA multiple of Mentice?Current EBITDA multiple of Mentice is 31.3x.
What is the current FCF of Mentice?Mentice's last 12 months FCF is ($392K).
What is Mentice's FCF margin?Mentice's last 12 months FCF margin is (1%).
What is the current EV/FCF multiple of Mentice?Current FCF multiple of Mentice is (104.9x).
How many companies Mentice has acquired to date?As of June 2026, Mentice has acquired 4 companies.
What was the largest acquisition by Mentice?$6M acquisition of Vascular Simulations on 1st October 2020 was the largest M&A Mentice has done to date.
In how many companies Mentice has invested to date?Mentice hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Mentice

Lists including Mentice

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial